Key Client Fiduciary Advisors’s Novavax NVAX Stock Holding History

Key Client Fiduciary Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33	Closed	-$2K	–	122
2022 Q1	$2K	Buy	+33	New	+$2.94K	﹤0.01%	124

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Key Client Fiduciary Advisors's NVAX Position: Q2 2022 in Review

Key Client Fiduciary Advisors sold out of Novavax (NVAX) in Q2 2022, closing a stake of 33 shares — an estimated $2K sold.

Key Client Fiduciary Advisors first reported a position in NVAX in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Key Client Fiduciary Advisors reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Key Client Fiduciary Advisors sold 33 Novavax shares in Q2 2022, an estimated $2K.
Key Client Fiduciary Advisors first reported a position in Novavax in Q1 2022 and held it in 1 quarter.
Key Client Fiduciary Advisors's Novavax position peaked at $2K in Q1 2022.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Key Client Fiduciary Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.